Patents by Inventor Anthony S. Prokopowicz

Anthony S. Prokopowicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Patent number: 6844435
    Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: January 18, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, III, Robert D. Selliah, Hidenori Takahashi
  • Pyrimidine derivatives useful as inhibitors of PKC-theta
    Publication number: 20040242613
    Abstract: Disclosed are novel compounds of formula (I): 1
    Type: Application
    Filed: January 27, 2004
    Publication date: December 2, 2004
    Applicants: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Mario G. Cardozo, Derek Cogan, Charles Lawrence Cywin, Georg Dahmann, Darren DiSalvo, John David Ginn, Anthony S. Prokopowicz, Denice M. Spero, Erick Young
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Patent number: 6770639
    Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, Ra, R4, R5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases associated with such kinases, for example, diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are processes for preparing these compounds, novel intermediates useful in these processes and compositions comprising compounds of the formula (I).
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: August 3, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Mario Cardozo, Daniel Goldberg, Abdelhakim Hammach, Tina Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, III, Hidenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Publication number: 20030207902
    Abstract: Disclosed are novel compounds of formula (I): 1
    Type: Application
    Filed: October 15, 2002
    Publication date: November 6, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, Robert D. Selliah, Hidenori Takahashi
  • Pyrimidine derivatives
    Publication number: 20030171359
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) 1
    Type: Application
    Filed: October 16, 2002
    Publication date: September 11, 2003
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoops, Steffen Steurer
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Publication number: 20030166929
    Abstract: Disclosed are novel compounds of formula (I): 1
    Type: Application
    Filed: November 12, 2002
    Publication date: September 4, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Mario G. Cardozo, Daniel R. Goldberg, Abdelhakim Hammach, Tina M. Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, Hindenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Patent number: 6506769
    Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, Ra, R4, R5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases associated with such kinases, for example, diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are processes for preparing these compounds, novel intermediates useful in these processes and compositions comprising compounds of the formula (I).
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: January 14, 2003
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Mario Cardozo, Daniel Goldberg, Abdelhakim Hammach, Tina Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, III, Hidenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Patent number: 6489328
    Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: December 3, 2002
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, III, Robert D. Selliah, Hidenori Takahashi
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Publication number: 20020119975
    Abstract: Disclosed are novel compounds of formula (I): 1
    Type: Application
    Filed: August 2, 2001
    Publication date: August 29, 2002
    Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, Robert D. Selliah, Hidenori Takahashi
  • Heterocyclic compounds useful as inhibitors of tyrosine kinases
    Publication number: 20020016460
    Abstract: Disclosed are novel compounds of formula (I): 1
    Type: Application
    Filed: August 2, 2001
    Publication date: February 7, 2002
    Inventors: Roger John Snow, Mario Cardozo, Daniel Goldberg, Abdelhakim Hammach, Tina Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, Hidenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang